The purpose of this study is to find the highest dosage of a two-drug combination — everolimus and BYL719 — that can be given safely in patients with advanced cancers that are large or have spread and cannot be cured with standard therapies.
Everolimus is approved for treating several types of cancer. It works by blocking mTOR, a protein that some cancer cells need to grow. BYL719 is an investigational drug that inhibits PI3 kinase, an enzyme which fuels the growth of several types of cancer.
Laboratory studies suggest that giving everolimus and BYL719 together may be more effective than giving either drug alone. Both drugs are taken orally (by mouth).